ArticleNanomedicine (London, England)2026
Stiripentol-loaded self-nanoemulsifying delivery system for glioblastoma: therapeutic efficacy in 3D spheroid and xenograft model.
Article in Nanomedicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial dysfunction and senescence accompany glioblastoma cell death triggered by a putative metabolic inhibitor.European journal of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimTo develop, formulate, and evaluate stiripentol (STP)-loaded Self-Nano Emulsifying Drug Delivery System (SNEDDS) for its potential as a Glioblastoma (GBM) therapeutic. MATERIALS AND
methodsCharacterization of STP SNEDDS using polydispersity index, particle size, zeta potential, and pH stability. Efficacy testing using BBB permeation, 3D spheroid, tumor xenograft, immunoblotting, immunohistochemistry, stability, and toxicity assessment.
resultsSTP SNEDDS showed improved water solubility and drug release profile, stability, relative safety in normal cells and brain tissue, and decreased 3D spheroid growth, tumor volume, tumor weight, and proliferative marker Ki67.
conclusionThis work highlights the potential of STP SNEDDS as a potential therapeutic for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.